Patriot Financial Group Insurance Agency LLC Acquires 11,399 Shares of Merck & Co., Inc. $MRK

Key Points

• Patriot Financial Group Insurance Agency LLC more than doubled its Merck stake in the first quarter, buying 11,399 additional shares and bringing its total holdings to 21,332 shares worth about $2.57 million.
• Merck reported better-than-expected first-quarter results, with EPS of -$1.28 versus an expected -$1.47 and revenue of $16.29 billion versus estimates of $15.85 billion, while reaffirming FY2026 EPS guidance of $5.04 to $5.16.
• The company also recently announced a quarterly dividend of $0.85 per share and has seen multiple analyst updates, leaving the stock with a consensus rating of Moderate Buy and an average price target of $128.72.

Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 114.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,332 shares of the company's stock after buying an additional 11,399 shares during the period. Patriot Financial Group Insurance Agency LLC's holdings in Merck & Co., Inc. were worth $2,566,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $26,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter valued at about $31,000. Finally, High Note Wealth LLC lifted its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after acquiring an additional 109 shares during the period. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $128.35 on Monday. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $128.78. The business has a 50-day simple moving average of $116.08 and a two-hundred day simple moving average of $114.43. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market cap of $316.99 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 2.89 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts' expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio is 95.77%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on MRK shares. Wells Fargo & Company cut their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating on the stock in a report on Friday, May 1st. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 target price for the company. Wall Street Zen raised Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, June 6th. Finally, Weiss Ratings downgraded Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $128.72.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.